U.S. Markets closed

uniQure N.V. (QURE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.30-0.29 (-1.65%)
At close: 04:00PM EDT
18.11 +0.81 (+4.68%)
After hours: 07:51PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close17.59
Bid15.75 x 1200
Ask22.00 x 1000
Day's Range16.99 - 17.46
52 Week Range12.52 - 36.55
Avg. Volume693,885
Market Cap799.506M
Beta (5Y Monthly)0.88
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    uniQure to Participate in Upcoming Industry Conferences in September

    LEXINGTON, Mass. and AMSTERDAM, Sept. 06, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Citi’s 17th Annual BioPharma Conference, September 7 – 8, 2022 Members of uniQure’s management team, including Matt Kapusta, chief executive officer, and Ricardo Dolmetsch, Ph.D., president of research

  • GlobeNewswire

    uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

    ~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington’s disease showed the investigative gene therapy was generally well tolerated at this dose with a mean reduction of 53.8% of mutant Huntingtin protein (mHTT) observed in cerebral spinal fluid (CSF) ~ ~ Announced postponement of AMT-130 higher-dose procedures due to recent suspected unexpected severe adverse reactions at this dose; Lower-dose procedures are not affected and no impact is expected on anticipated data readout

  • GlobeNewswire

    uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

    Bar Chart Bar Chart ~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT (mHTT) observed in cerebral spinal fluid (CSF) at 12 months in evaluable patients treated with AMT-130 ~ ~ Neurofilament Light Chain (NfL) in CSF near baseline at 12 months in patients treated with AMT-130 ~ ~ Biomarker and clinical data including 24-month follow-up in the low-dose U.S. cohort a